协议正式化了先前宣布的谅解备忘录后的初步可行性阶段
加拿大不列颠哥伦比亚省温哥华 --（Newsfile Corp. -2026 年 1 月 22 日）- FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0)（以下简称 “ 公司” 或 “ FendX”），是一家开发基于技术的解决方案以减少有害病原体传播的创新表面保护公司，欣然宣布已于 2026 年 1 月 20 日与美国环保消毒剂制造商 Aquaox LLC（“ Aquaox”）签署了一份合作协议（以下简称 “ 协议”）。
该协议建立在公司与 Aquaox 于 2025 年 11 月 18 日签署的谅解备忘录（“ MOU”）的基础上，并正式化了合作的初步阶段。在此阶段，双方将评估技术可行性，并确认可靠配制抗微生物剂的能力。成功完成后，合作可能会推进到最终确定用于产品开发的新型抗微生物剂。
“我们很高兴正式化这项合作，这代表了我们与 Aquaox 关系的一个重要下一步，” FendX 首席执行官 Carolyn Myers 博士表示。“这项合作支持我们对新型抗微生物剂的评估，这些剂可能会为未来的产品提供支持。”
“正式化这项协议为我们与 FendX 的合作提供了评估我们抗微生物技术的可行性和性能的框架，” Aquaox 首席执行官 Michel van Schaik 表示。“我们认为这是评估支持开发创新、环保健康和卫生技术解决方案的重要一步。”
该协议包括各方的终止条款，每一方对其自身的费用和支出负责。不能保证根据协议进行的合作工作会超出可行性阶段或导致进一步的正式协议、监管批准或商业产品的开发，或者根据谅解备忘录签署其他合作或供应协议。推进仍然受到多种因素的影响，包括但不限于技术评估、监管考虑和额外协议的签署。
关于 FendX Technologies Inc.
FendX 是一家开发创新解决方案以帮助减少日常环境中有害病原体传播的表面保护公司。利用专有技术，公司正在推进一系列保护性表面涂层，包括 REPELWRAP™薄膜、一种基于液体的纳米涂层技术和一种专门的 Foley 导尿管涂层。公司专注于在表面保护领域建立强大的知识产权组合，并致力于识别和推进增强医疗、消费和商业环境中卫生和安全的新技术和材料。了解更多信息，请访问：https://fendxtech.com。
关于 Aquaox LLC.
Aquaox LLC 是一家美国环保消毒剂制造商，专注于次氯酸（“ HOCl”）技术。该公司通过战略合作伙伴关系成功商业化其基于 HOCl 的化合物，促进了其在医疗、商业和工业领域的收入增长。Aquaox 致力于提供安全、可持续的替代传统化学消毒剂的方案。
代表公司
“ Carolyn Myers”
Carolyn Myers
首席执行官兼董事
加拿大证券交易所及市场监管机构（根据加拿大证券交易所政策中的定义）对本公告的充分性或准确性不承担任何责任。
前瞻性声明
本新闻稿包含某些符合加拿大证券法定义的前瞻性陈述，包括关于：公司的计划；根据协议提出的合作计划，包括评估技术可行性和确认可靠配制抗微生物剂的能力；关于合作可能推进至最终确定用于产品开发的新型抗微生物剂的陈述；关于评估可能有助于未来产品供应的新抗微生物剂的陈述；关于 FendX 开发和商业化新型病原体控制产品/卫生解决方案的陈述，包括其益处和拟定目标市场，包括医疗、消费和商业市场；关于扩展公司产品和知识产权组合的陈述；以及正在开发的产品及其相关的任何病原体减少益处。虽然公司相信这些陈述是合理的，但无法保证这些期望会被证明是正确的。这些陈述仅是预测，涉及已知和未知的风险，这些风险可能导致实际结果以及公司的计划和目标与前瞻性陈述中表达的内容有重大差异，包括：根据协议进行的合作工作可能不会超出可行性阶段或导致额外的合作和最终协议、供应协议、监管批准、新型抗微生物剂的开发或商业产品的开发；不利的市场条件；与公司筹集额外资金以完成所有计划活动（包括根据协议的倡议）相关的风险和不确定性；与每种薄膜、液体配方和导管涂层的研究和开发活动相关的风险，包括成功完成实际性能测试和必要时的放大计划；公司可能无法扩展其产品管道或执行其业务发展和增长计划的风险，包括无法开发任何新型抗微生物剂或产品，或无法因与 Aquaox 的合作而开发任何新知识产权；公司产品（包括可能开发的任何新产品）可能无法商业化的风险，如果商业化，可能不会被公众接受和采用的风险；公司未能如预期或根本未能获得必要的批准和/或许可的风险；政府监管对公司业务的影响；与公司获得和保护其知识产权的能力相关的风险；产品候选者仅处于配方/重新配方阶段；有限的运营历史；对合作伙伴、许可方和其他人的依赖；一般经济和政治条件的影响；以及公司控制之外的其他因素。尽管公司相信前瞻性陈述中反映的期望是合理的，但无法保证未来的结果、活动水平或表现。此外，任何前瞻性陈述仅在作出该陈述的日期有效，除非适用法律要求，公司不承担更新任何前瞻性陈述的义务，以反映该陈述作出日期之后的事件或情况，或反映意外事件的发生。新因素不时出现，管理层无法预测所有这些因素，也无法提前评估这些因素对公司业务的影响或任何因素或因素组合可能导致实际结果与任何前瞻性陈述中包含的内容有重大差异的程度。读者应查阅此处列出的所有信息，并应参考公司在 SEDAR+ 上向不列颠哥伦比亚证券委员会提交的风险因素披露。
<img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9526/281311_98d67a71141bfa6c_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9526/281311_98d67a71141bfa6c_logo.jpg"/>
要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/281311
<img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/281311/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/281311/375"/>

FMTOF

FMTO

FendX Technologies Inc. 与 Aquaox LLC 签署了一项合作协议，以评估开发环保抗菌剂的可行性。该协议正式确立了双方合作的初始阶段，基于之前签署的谅解备忘录。两家公司旨在评估并可能最终确定用于产品开发的新型抗菌剂。此次合作需考虑多种因素，包括技术评估和监管批准。FendX 专注于创新的表面保护解决方案，而 Aquaox 则专注于环保的消毒剂

Agreement formalizes initial feasibility phase following previously announced MOU
<div class="lb-trans">协议正式化了先前宣布的谅解备忘录后的初步可行性阶段
</div>Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0)(the &#34; Company&#34; or &#34; FendX&#34;), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it has entered into a collaboration agreement (the &#34; Agreement&#34;) dated January 20, 2026 with Aquaox LLC (&#34; Aquaox&#34;), a U.S. based manufacturer of environmentally responsible disinfectants.
<div class="lb-trans">加拿大不列颠哥伦比亚省温哥华 --（Newsfile Corp. -2026 年 1 月 22 日）- FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0)（以下简称 “ 公司” 或 “ FendX”），是一家开发基于技术的解决方案以减少有害病原体传播的创新表面保护公司，欣然宣布已于 2026 年 1 月 20 日与美国环保消毒剂制造商 Aquaox LLC（“ Aquaox”）签署了一份合作协议（以下简称 “ 协议”）。
</div>The Agreement builds upon the Memorandum of Understanding (&#34; MOU&#34;) signed between the Company and Aquaox announced November 18, 2025 and formalizes the initial phase of the collaboration. During this phase, the parties will assess technical feasibility and confirm the ability to reliably formulate antimicrobial agents. Upon successful completion, the collaboration may advance toward finalizing novel antimicrobial agents for use in product development.
<div class="lb-trans">该协议建立在公司与 Aquaox 于 2025 年 11 月 18 日签署的谅解备忘录（“ MOU”）的基础上，并正式化了合作的初步阶段。在此阶段，双方将评估技术可行性，并确认可靠配制抗微生物剂的能力。成功完成后，合作可能会推进到最终确定用于产品开发的新型抗微生物剂。
</div>&#34;We are pleased to formalize this collaboration, which represents a meaningful next step in our relationship with Aquaox,&#34; said Dr. Carolyn Myers, CEO of FendX. &#34;This collaboration supports our evaluation of new antimicrobial agents that could contribute to future product offerings.&#34;
<div class="lb-trans">“我们很高兴正式化这项合作，这代表了我们与 Aquaox 关系的一个重要下一步，” FendX 首席执行官 Carolyn Myers 博士表示。“这项合作支持我们对新型抗微生物剂的评估，这些剂可能会为未来的产品提供支持。”
</div>&#34;Formalizing this agreement provides a framework to evaluate the feasibility and performance of our antimicrobial technology in collaboration with FendX,&#34; said Michel van Schaik, CEO of Aquaox. &#34;We see this as an important step in assessing solutions that support the development of innovative, eco-friendly technologies for health and hygiene.&#34;
<div class="lb-trans">“正式化这项协议为我们与 FendX 的合作提供了评估我们抗微生物技术的可行性和性能的框架，” Aquaox 首席执行官 Michel van Schaik 表示。“我们认为这是评估支持开发创新、环保健康和卫生技术解决方案的重要一步。”
</div>The Agreement includes termination provisions for each party, and each party is responsible for their own costs and expenses. There can be no assurance that the collaboration work pursuant to the Agreement will progress beyond the feasibility phase or result in further definitive agreements, regulatory approvals, or development of commercial products, or that other collaboration or supply agreements will be entered into pursuant to the MOU. Advancement remains subject to several considerations, including but not limited to, technical evaluation, regulatory considerations, and the execution of additional agreements.
<div class="lb-trans">该协议包括各方的终止条款，每一方对其自身的费用和支出负责。不能保证根据协议进行的合作工作会超出可行性阶段或导致进一步的正式协议、监管批准或商业产品的开发，或者根据谅解备忘录签署其他合作或供应协议。推进仍然受到多种因素的影响，包括但不限于技术评估、监管考虑和额外协议的签署。
</div>About FendX Technologies Inc.
<div class="lb-trans">关于 FendX Technologies Inc.
</div>FendX is a surface protection company developing innovative solutions to help reduce the spread of harmful pathogens in everyday environments. Leveraging proprietary technologies, the Company is advancing a portfolio of protective surface coatings, including REPELWRAP™ film, a liquid-based nano- coating technology and a specialized Foley catheter coating. The Company is focussed on building a robust intellectual property portfolio in the surface protection space and is committed to identifying and advancing new technologies and materials that enhance hygiene and safety across healthcare, consumer and commercial settings. Learn more at: https://fendxtech.com.
<div class="lb-trans">FendX 是一家开发创新解决方案以帮助减少日常环境中有害病原体传播的表面保护公司。利用专有技术，公司正在推进一系列保护性表面涂层，包括 REPELWRAP™薄膜、一种基于液体的纳米涂层技术和一种专门的 Foley 导尿管涂层。公司专注于在表面保护领域建立强大的知识产权组合，并致力于识别和推进增强医疗、消费和商业环境中卫生和安全的新技术和材料。了解更多信息，请访问：https://fendxtech.com。
</div>About Aquaox LLC.
<div class="lb-trans">关于 Aquaox LLC.
</div>Aquaox LLC is a U.S.-based manufacturer of environmentally responsible disinfectants, specializing in hypochlorous acid (&#34; HOCl&#34;) technologies. The company has successfully commercialized its HOCl-based compounds through strategic partnerships, contributing to their revenue growth across healthcare, commercial, and industrial sectors. Aquaox is committed to delivering safe, sustainable alternatives to conventional chemical disinfectants.
<div class="lb-trans">Aquaox LLC 是一家美国环保消毒剂制造商，专注于次氯酸（“ HOCl”）技术。该公司通过战略合作伙伴关系成功商业化其基于 HOCl 的化合物，促进了其在医疗、商业和工业领域的收入增长。Aquaox 致力于提供安全、可持续的替代传统化学消毒剂的方案。
</div>ON BEHALF OF THE COMPANY
<div class="lb-trans">代表公司
</div>&#34; Carolyn Myers&#34;
<div class="lb-trans">“ Carolyn Myers”
</div>Carolyn Myers
<div class="lb-trans">Carolyn Myers
</div>Chief Executive Officer and Director
<div class="lb-trans">首席执行官兼董事
</div>Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
<div class="lb-trans">加拿大证券交易所及市场监管机构（根据加拿大证券交易所政策中的定义）对本公告的充分性或准确性不承担任何责任。
</div>Forward-Looking Statements
<div class="lb-trans">前瞻性声明
</div>This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; the proposed collaboration plans pursuant the Agreement including assessing technical feasibility and confirming the ability to reliably formulate antimicrobial agents; statements regarding the collaboration may advance toward finalizing novel antimicrobial agents for use in product development; statements regarding evaluation of new antimicrobial agents that could contribute to future product offerings; statements regarding the development and commercialization of new pathogen-control products/hygiene solutions by FendX, including their benefits and proposed target markets including healthcare, consumer and commercial markets; statements regarding expanding the Company's product and IP portfolio; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking statements, including: risks that the collaboration work pursuant to the Agreement will not progress beyond the feasibility phase or result in additional collaboration and definitive agreements, supply agreements, regulatory approvals, development of novel antimicrobial agents or development of commercial products; adverse market conditions; risks and uncertainties associated with the Company's ability to raise additional capital to complete all of its planned activities including initiatives pursuant to the Agreement; risks related to research and development activities for each of the film, liquid formulation and catheter coating, including successful completion of real world performance testing and scale-up initiatives, if required; risks that the Company may not expand its product pipeline or execute its business development and growth plans, including not being able to develop any novel antimicrobial agents or products nor develop any new intellectual property as a result of its collaboration with Aquaox; risks that the Company's products, including any new products that may be developed, may not be commercialized, and if they are commercialized, that they may not be accepted and adopted by the public; the risk that the Company will not obtain necessary approvals and/or clearances as anticipated or at all; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its IP; product candidates only being in formulation/reformulation stages; limited operating history; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's filings with the British Columbia Securities Commission on SEDAR+ at www.sedarplus.ca .
<div class="lb-trans">本新闻稿包含某些符合加拿大证券法定义的前瞻性陈述，包括关于：公司的计划；根据协议提出的合作计划，包括评估技术可行性和确认可靠配制抗微生物剂的能力；关于合作可能推进至最终确定用于产品开发的新型抗微生物剂的陈述；关于评估可能有助于未来产品供应的新抗微生物剂的陈述；关于 FendX 开发和商业化新型病原体控制产品/卫生解决方案的陈述，包括其益处和拟定目标市场，包括医疗、消费和商业市场；关于扩展公司产品和知识产权组合的陈述；以及正在开发的产品及其相关的任何病原体减少益处。虽然公司相信这些陈述是合理的，但无法保证这些期望会被证明是正确的。这些陈述仅是预测，涉及已知和未知的风险，这些风险可能导致实际结果以及公司的计划和目标与前瞻性陈述中表达的内容有重大差异，包括：根据协议进行的合作工作可能不会超出可行性阶段或导致额外的合作和最终协议、供应协议、监管批准、新型抗微生物剂的开发或商业产品的开发；不利的市场条件；与公司筹集额外资金以完成所有计划活动（包括根据协议的倡议）相关的风险和不确定性；与每种薄膜、液体配方和导管涂层的研究和开发活动相关的风险，包括成功完成实际性能测试和必要时的放大计划；公司可能无法扩展其产品管道或执行其业务发展和增长计划的风险，包括无法开发任何新型抗微生物剂或产品，或无法因与 Aquaox 的合作而开发任何新知识产权；公司产品（包括可能开发的任何新产品）可能无法商业化的风险，如果商业化，可能不会被公众接受和采用的风险；公司未能如预期或根本未能获得必要的批准和/或许可的风险；政府监管对公司业务的影响；与公司获得和保护其知识产权的能力相关的风险；产品候选者仅处于配方/重新配方阶段；有限的运营历史；对合作伙伴、许可方和其他人的依赖；一般经济和政治条件的影响；以及公司控制之外的其他因素。尽管公司相信前瞻性陈述中反映的期望是合理的，但无法保证未来的结果、活动水平或表现。此外，任何前瞻性陈述仅在作出该陈述的日期有效，除非适用法律要求，公司不承担更新任何前瞻性陈述的义务，以反映该陈述作出日期之后的事件或情况，或反映意外事件的发生。新因素不时出现，管理层无法预测所有这些因素，也无法提前评估这些因素对公司业务的影响或任何因素或因素组合可能导致实际结果与任何前瞻性陈述中包含的内容有重大差异的程度。读者应查阅此处列出的所有信息，并应参考公司在 SEDAR+ 上向不列颠哥伦比亚证券委员会提交的风险因素披露。
</div><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9526/281311_98d67a71141bfa6c_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/9526/281311_98d67a71141bfa6c_logo.jpg"/>
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281311
<div class="lb-trans">要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/281311
</div><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/281311/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/281311/375"/>

FendX 与 Aquaox 签署合作协议，共同致力于环保抗菌剂的创新 | FDXTF 股票新闻